WELCOME TO The Biotechnology REPORT
Bridging the Gaps
I'm For Real
Enter your details once to access all our information and resources
MP Biomedicals is dedicated to giving scientists and researchers innovative, quality tools and superior service to aid them in their quest for ground-breaking discovery and turning the hope for life-changing solutions into a reality.
whitePaper | March 16, 2021
Cell and gene therapies have emerged as a new treatment paradigm, and with them has come the potential
to alter the course of many rare diseases. In many cases, there is an opportunity to correct the underlying
dysfunction with a one-time administration of a therapy and provide either a functional cure or a substantial
improvement in health outcomes. In other cases, long term symptom relief will be the primary therapeutic
objective. Some of these indications may require more than one dose to achieve continued symptom relief
and scientists and companies are working on technologies that will enable the use of a repeat dose.
whitePaper | November 12, 2019
This document describes a novel Quanterix lysate diluent for running lysate samples with Simoa assays diluent.
whitePaper | April 14, 2021
Delivering Covid-19 vaccines to 7.8 billion people is a daunting challenge that will stretch supply chains past their limits.
Even if all the needed doses were ready today, vaccine manufacturers still must find solutions to deliver multiple doses of those vaccines to most people on the planet.
To read more, please download this free white paper.
whitePaper | November 21, 2019
Our Accounting and Finance team has published an overview of the accounting and finance challenges facing the Biopharmaceutical industry and interrelated Biotechnology organizations.
whitePaper | April 16, 2020
Accurate diagnosis is the cornerstone of medicine; it is essential for informed care and promoting patient and family well-being. However, families with a rare genetic disease (RGD) often spend more than five years on a diagnostic odyssey of specialist visits and invasive testing that is lengthy, costly, and often futile, as 50% of patients do not receive a molecular diagnosis.
whitePaper | September 17, 2021
The adoption of CAR T therapies in the UK NHS is a success story, especially seen in
relation to the experience in many other countries. The UK NHS showed itself to be agile,
and responsive to addressing the unique challenges these therapies present, which
facilitated access to patients earlier than in many other countries. (including delivery centre
selection, development of service specifications, collaboration with manufacturers
throughout the preparation phase for adoption, establishment of national multidisciplinary
CAR T team to ensure equity of access and prioritization of resources (where needed)).
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE